Lyell Immunopharma (LYEL) Insider Ltd Sells 76,000 Shares

Innovative Cellular Therapeutics Holdings Ltd recently sold 76,000 shares of LYEL on June 29, 2026. The shares traded near $14.05 on Wednesday. This transaction was not part of a pre-planned trading program.

Other Institutional Activity in LYEL

ARCH Venture Management, LLC grew its holdings of LYEL by 488,090 shares, ending with 3,247,162 shares worth about $65.1 million. GSK PLC maintained its position with 1,512,659 shares valued at $30.3 million. Similarly, Foresite Capital Management IV, LLC held steady at 800,399 shares, valued at approximately $16.1 million. Orland Properties Ltd also kept its stake unchanged with 754,698 shares worth about $15.1 million. Meanwhile, Vanguard Capital Management LLC opened a new position, acquiring 718,155 shares valued at $14.4 million.

Insider Buying and Selling at Lyell Immunopharma, Inc.

Innovative Cellular Therapeutics Holdings Ltd sold 76,000 shares on June 29, 2026, and 66,500 shares on June 15, 2026. Other insider transactions included Gary Lee, Chief Scientific Officer, selling 130 shares at $18.92 on May 11, 2026. Stephen Hill, Chief Operating Officer, sold 89 shares at the same price. Veronica Sanchez Bulis, VP, Corporate Controller, sold 217 shares at $18.91, and Lynn Seely, President and CEO, sold 388 shares at the same price.

Analysts Set New Price Targets

On June 9, 2026, HC Wainwright & Co. reiterated a buy rating for LYEL, setting a price target of $45. Needham also reiterated its buy rating with a $44 target on June 8, 2026. The consensus among analysts is a buy recommendation with a target mean price, reflecting strong interest in the stock.

Bottom Line

Innovative Cellular Therapeutics Holdings Ltd's recent sale of LYEL shares is part of ongoing insider activity. The transactions offer a glimpse into the company's internal moves, which investors often monitor closely. Meanwhile, ARCH Venture Management's increased stake shows confidence in LYEL. Analyst ratings remain positive, with reiterated buy ratings and high price targets, suggesting continued interest in the company's prospects. As always, these insights are based on past filings and may not reflect current positions.